Compare Ares Capital Corporation (ARCC) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ares Capital Corporation vs Charles River Laboratories Intl. Inc — how do they compare? Ares Capital Corporation trades at $19.95 (market cap $14.34B), while Charles River Laboratories Intl. Inc trades at $282 (market cap $13.46B). The key difference: Ares Capital Corporation and Charles River Laboratories Intl. Inc are close in size by market cap, and Ares Capital Corporation pays a 9.61% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| ARCC | CRL | |
|---|---|---|
Market Cap | $14.34B | $13.46B |
Sector | Financials | Health |
52-Week High | $22.68 | $282.00 |
52-Week Low | $17.45 | $145.57 |
Dividend Yield | 9.61% | — |
Enterprise Value | — | $16.30B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ares Capital Corporation
Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.
Read more on ARCC →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
